Home / Market News / $TEVA
benzinga Corporate Catalyst Impact 75/100 ● positive

Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer

Sep 28, 2026, 8:01 PM UTC · Primary ticker $TEVA

Teva Pharmaceutical Industries announced FDA approval for DEGEVMA, a biosimilar to Xgeva, for treating bone complications in advanced cancer patients. This approval expands Teva's biosimilar portfolio and increases access to treatment options in oncology-related bone disease, potentially impacting market share for the original drug.

Teva Pharmaceutical Industries received FDA approval for DEGEVMA, a biosimilar to Amgen's Xgeva, for treating bone complications in advanced cancer. This is a significant positive for Teva as it expands their biosimilar portfolio, following the earlier approval of PONLIMSI, and allows them to compete in a lucrative market. For Amgen, the developer of the original Xgeva, this introduces direct competition, which could lead to price erosion and market share loss. In the short term, Teva may see a boost in investor confidence and potential revenue growth, while Amgen could face downward pressure. Long-term, the biosimilar market is expected to grow, offering opportunities for companies like Teva, but also posing a continuous threat to originator drug manufacturers.

$TEVA positive FDA approval of new biosimilar product
$AMGN negative Increased competition for Xgeva
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.